Brii Biosciences Expands Infectious Disease Pipeline
(WorldNews Business)

BEIJING & DURHAM, N.C.--(BUSINESS WIRE)--Nov 21, 2019-- Brii Biosciences, a clinical-stage company committed to serving patients´ needs and improving public health in China and around the world, today announced a series of partnerships to develop and commercialize novel anti-infective agents to treat drug-resistant and otherwise difficult-to-treat pathogens. Under the terms of the agreements, Brii Bio will develop up to seven compounds from clinical proof-of-concept through to commercialization, bringing the total number of partnered assets in the company´s pipeline up to 12, in addition to internal development efforts underway. `Brii Bio began with a major effort in infectious diseases...